Vantage Wealth Has $21.69 Million Stake in Amgen Inc. (NASDAQ:AMGN)

Vantage Wealth raised its position in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 4.2% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 69,614 shares of the medical research company's stock after purchasing an additional 2,813 shares during the period. Amgen accounts for approximately 4.9% of Vantage Wealth's holdings, making the stock its 2nd biggest position. Vantage Wealth's holdings in Amgen were worth $21,688,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Vanguard Group Inc. grew its holdings in shares of Amgen by 0.6% during the fourth quarter. Vanguard Group Inc. now owns 52,721,795 shares of the medical research company's stock valued at $13,741,409,000 after buying an additional 339,522 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its position in Amgen by 25.4% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 13,205,604 shares of the medical research company's stock worth $3,441,909,000 after purchasing an additional 2,672,975 shares during the period. Geode Capital Management LLC raised its position in Amgen by 2.9% in the fourth quarter. Geode Capital Management LLC now owns 12,475,032 shares of the medical research company's stock worth $3,245,881,000 after purchasing an additional 352,143 shares in the last quarter. Capital International Investors grew its holdings in shares of Amgen by 40.1% in the 4th quarter. Capital International Investors now owns 12,212,065 shares of the medical research company's stock worth $3,182,843,000 after purchasing an additional 3,495,503 shares during the last quarter. Finally, Capital World Investors raised its position in Amgen by 1,292.0% in the 4th quarter. Capital World Investors now owns 6,495,710 shares of the medical research company's stock valued at $1,693,042,000 after purchasing an additional 6,029,058 shares during the last quarter. Institutional investors own 76.50% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on AMGN. Mizuho upped their price target on Amgen from $235.00 to $280.00 and gave the company a "neutral" rating in a research note on Wednesday, May 7th. Royal Bank of Canada dropped their target price on Amgen from $324.00 to $320.00 and set an "outperform" rating on the stock in a report on Friday, May 2nd. Erste Group Bank cut Amgen from a "strong-buy" rating to a "hold" rating in a report on Thursday, May 8th. Johnson Rice set a $294.00 target price on Amgen in a report on Wednesday, March 5th. Finally, Cantor Fitzgerald assumed coverage on shares of Amgen in a report on Tuesday, April 22nd. They set a "neutral" rating and a $305.00 target price for the company. Two analysts have rated the stock with a sell rating, twelve have given a hold rating, nine have assigned a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat.com, Amgen presently has an average rating of "Hold" and a consensus target price of $309.22.

Amgen Price Performance

Shares of AMGN traded up $0.09 during trading hours on Thursday, reaching $287.10. 2,517,436 shares of the stock traded hands, compared to its average volume of 2,805,485. The company has a market cap of $154.38 billion, a P/E ratio of 38.03, a price-to-earnings-growth ratio of 2.63 and a beta of 0.51. The company has a current ratio of 1.26, a quick ratio of 0.95 and a debt-to-equity ratio of 9.62. Amgen Inc. has a 52-week low of $253.30 and a 52-week high of $346.85. The company's 50-day moving average price is $282.39 and its two-hundred day moving average price is $285.31.

Amgen (NASDAQ:AMGN - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The medical research company reported $4.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.18 by $0.72. Amgen had a return on equity of 176.32% and a net margin of 12.24%. The business had revenue of $8.15 billion for the quarter, compared to analysts' expectations of $8.05 billion. During the same period in the prior year, the firm earned $3.96 EPS. The company's revenue for the quarter was up 9.4% on a year-over-year basis. On average, analysts anticipate that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.